CellTrend产品代理

The   successful development and application of new drugs is increasingly tied to   the latest progress in biotechnology and biochemistry. CellTrend enables its   customers to capitalize on the synergies between pharmacy and   biochemistry/biotechnology. Our experienced research and management team   brings together a broad base of knowledge in modern biochemistry and clinical   pharmacy. The team consists of pharmacists and medical doctors who are very   familiar with the requirements involved in the development and application of   medicinal drugs.

CellTrend   offers the following technologies and services:

Cell culture   systems for research on active substances (Bioassays)

Development   and production of antibody-based detection systems

Individual   pharmacotherapy (outsourced in the Center of molecular Oncology)

Bioassays

In vitro cultivation of eukaryotic cells is an ideal compromise between controversial animal experiments and simple test systems using only single biological components like enzymes. Cell cultures are increasingly used in pharmaceutical and cosmetics industries as a cost effective and reliable method to

evaluate   toxicity and efficacy in the development of new active agents.

CellTrend   offers techniques and equipment for cell culture testing. Our main focus is   on complex functional tests (e.g. angiogenesis, cell migration, NCI60   screening, immune cell func­tions, cytokine secretion). Study designs as well as the test   systems themselves are individually adapted to customers needs.

Immuno-Assays

Furthermore,   CellTrend develops, produces, and distributes Immuno-Assays e.g. ELISAs   (enzyme linked immuno sorbend assay) which is a quick and sensitive   analytical method that is characterized by specific binding of antibodies to   analytes. Various validated diagnostic and research test kits are available.   If required, samples are analysed in CellTrend laboratories. We also offer to   develop new ELISAs for your analytes.

In 2006 CellTrend developed the ELISA for the determination of Auto-Antibodies against the Angiotensin-II-Receptor-I. The assay is patented worldwide (European patent number 1393076). The assay is validated according the Guidance for Industry: Bioanalytical Method Validation, US FDA May 2001.